(OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary has officially entered the European cannabigerol (CBG) market with the release of its Kannaway® Premium CBG made with Organic Hemp Seed Oil.
“Since launching in Europe in 2018, Europe has become one of our best revenue-generating markets as consumers have responded very positively to Kannaway’s wide range of cannabidiol (CBD) products,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Similar to CBD, CBG is non-psychoactive, meaning it does not cause intoxicating effects. Researchers have conducted and are currently conducting many interesting studies on CBG. We are excited to broaden our product offerings with CBG and are confident the market will be as well.”
Each bottle of Kannaway® Premium CBG made with Organic Hemp Seed Oil contains 500 mg of CBG and 200 mg of CBD. The cannabinoids used in the product are derived from organic European hemp and quality certified through the Company’s Triple Lab Testing® process to deliver the potential natural benefits of hemp-based cannabinoids.
“As CBD continues to grow in acceptance around the world, the market for cannabinoids like CBG also expands,” said Kannaway CEO Blake Schroeder. “Our company intends to continue to be at the forefront of expanding access to cannabinoids just as we have been with CBD.”
To learn more about these products, please visit .
is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.
About Medical Marijuana, Inc.
. Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by and ; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including and . Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at or by visiting . To see Medical Marijuana, Inc.’s corporate video, .
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations Contact:
Investor Relations Contact:
P. (858) 283-4016